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Early identification of causal genetic variants underlying antimalarial drug resistance could provide robust
epidemiological tools for timely public health interventions. Using a novel natural genetics strategy for
mapping novel candidate genes we analyzed.75,000 high quality single nucleotide polymorphisms selected
from high-resolution whole-genome sequencing data in 27 isolates of Plasmodium falciparum. We
identified genetic variants associated with susceptibility to dihydroartemisinin that implicate one region on
chromosome 13, a candidate gene on chromosome 1 (PFA0220w, a UBP1 ortholog) and others (PFB0560w,
PFB0630c, PFF0445w) with putative roles in protein homeostasis and stress response. There was a strong
signal for positive selection on PFA0220w, but not the other candidate loci. Our results demonstrate the
power of full-genome sequencing-based association studies for uncovering candidate genes that determine
parasite sensitivity to artemisinins. Our study provides a unique reference for the interpretation of results
from resistant infections.
A
ntimalarial drug resistance has repeatedly frustrated global efforts to limit morbidity and prevent mor-
tality from Plasmodium falciparummalaria. Recently, landmark studies conducted inWestern Cambodia
in patients who had been treated with artemisinin derivatives have reported an alarming delay in parasite
clearance1,2. Since then, infections with increasingly delayed clearance were also reported fromWestern Thailand
and it was suggested that this in vivo phenotype is genetically determined3. Because artemisinin-based combina-
tion chemotherapies are the backbone of global malaria control programs, this situation constitutes a public
health emergency. Historically, Southeast Asia has been the origin of global spread of drug resistance-conferring
mutations. The reason for this geographical bias is only partially understood, but ecological, behavioral and
biological factors that may play a role include high rates of inbreeding in the mosquito vector, which reduce
competition and favor clonal expansion of emerging genetic variants under drug pressure4, indiscriminate use of
poor-quality drugs5 and possibly, ‘‘hyper-mutant’’ parasite strains6.
High throughput whole-genome sequencing technology has revolutionized the approach for identifying gen-
etic variants associated with phenotypes of interest in natural populations.We have harnessed this natural genetic
strategy for identifying novel candidate genes thatmodify the susceptibility of P. falciparum to antimalarial drugs.
We hypothesized that the range of phenotypic variation observed in natural populations of P. falciparum is hard-
wired to naturally occurring genetic variants, termed ‘standing variation’, without necessarily reflecting ‘‘resist-
ance’’ as an evolutionary adaptation to selective pressure7,8. Here we present the results of a genome-wide study in
27 isolates of Plasmodium falciparum obtained from malaria patients in Kilifi, Kenya.
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Results
In vitro phenotyping of P. falciparum isolates from Kenyan
malaria patients. Fully culture adapted P. falciparum isolates
obtained from pediatric patients enrolled in a clinical trial in Kilifi
District, Kenya9 were subjected to independently repeated growth
inhibition assays to obtain reproducible drug sensitivity phenotypes
(expressed as half-maximal inhibitory concentration; IC50). We
focused on a panel of 8 common antimalarial drugs based on their
importance as former (chloroquine, CQ; pyrimethamine, PM; and
desethyl-amodiaquine, DEAQ) and current (dihydroartemisinin,
DHA; lumefantrine, LM; piperaquine, PPQ; and quinine, QN) first
or second line antimalarial treatments in Kenya. Mefloquine (MQ)
was added because of its global importance for treating and pre-
venting malaria. The median IC50 values (range) were 37 nM (12–
310) for CQ; 22 mM(3–70) for PM; 22 nM (7–120) for DEAQ; 2 nM
(0.5–4) for DHA; 17 nM (4–85) for LM; 49 nM (24–122) for PPQ;
60 nM (12–140) for QN; and 29 nM (7–99) for MQ. The intra-
sample correlation between IC50 assay replicates (a measure of
reproducibility) was high (median: 0.97, range: 0.90–0.99). The
median correlation between drug assays was 0.18, and varied
between 0.01 (lumefantrine and quinine) and 0.76 (LM and MQ)
(see Figure 1 for a summary of the assays). The observed pattern of
correlations (Fig. 1) was consistent with previously published data
(e.g., DHA and LM, 0.46 and DHA and MQ, 0.58)10,11. We did not
classify isolates into sensitive and resistant categories for several
reasons. First, there is no general consensus on in vitro cutoff
values and their relevance for in vivo resistance can be obscured by
unrelated parameters (primarily, of pharmacokinetic and immuno-
logical nature). For the artemisinin class of drugs, only recently
studies started to address the relationship between specialized no-
vel in vitro assays (not done here) and the delayed parasite clearance
phenotype observed in vivo12. Secondly, there is increased statistical
power in using quantitative, as opposed to qualitative, data for
association analyses.
Whole genome sequence analysis. The sequencing technology
yielded a median of 18.7 (range: 8.6–38.8) million 54–76 base-pair
reads across the 27 samples. Mapping uniquely the reads to the
reference 3D7 genome13 yielded a genome-wide average of 57.3-
fold coverage, and a median of 86.2% of the genome being co-
vered, 69.6% to at least a five-fold coverage level. The average
number of allelic differences to 3D7 (at an error rate of 1 per 1000)
was 8899/strain, and across all samples 182,357 positions were
identified, leading to 75,471 high quality bi-allelic SNPs (with
,10% missing alleles per position among all samples, minor allele
frequency of 5%) carried forward for further analysis. The vast ma-
jority of SNPs (66,966, 88.7%) contained no heterozygous genotype
calls. Overall, only 0.6% of genotype calls were heterozygous,
potentially indicative that few infections/isolates were multi-clonal.
Using a principal component analysis on the SNPs, there was no
evidence of any samples being continental outliers or identical
genetically (for instance, due to potential contamination) (Fig. S1).
Association analysis. Because of the observed deviation from a nor-
mal distribution of in vitro responses (Fig. 1) we applied a conser-
vative non-parametric tests for the phenotype-genotype association
analysis (Table 1, Table S1). We observed ten-fold differences in the
range of IC50 values (the ‘effect size’) for chloroquine and DHA
(Figure 1), with standard deviations of measurements of at most
30% of values14. With a sample size of 27, we would expect to have
over 95% power (5% type I error) to detect a 3-fold difference using a
Wilcoxon text at a minimum allele frequency of 7.4% (2/27).
Similarly, we are able to detect a two-fold difference at a minimum
allele frequency of 11.1% (3/27).
In a first analysis, we sought to internally validate our approach by
using chloroquine resistance as reference. Indeed, we identified
MAL7P1.27, which encodes the chloroquine resistance transporter
(CRT), as the most significant association hit covered by four coding
SNPs (P # 1024) on chromosome 7 (Table S1, Fig. S1).
Based on these reassuring results, we instituted a screen for asso-
ciations with susceptibilities to 8 drugs. The following number of
SNPs (genes, intergenic positions not listed) were lower than the
computed significance threshold of 7 3 1024 (Table 1): (i) 2 hits
for PPQ (PF07_0019), (ii) 1 hit for LM (0), 5 hits for DHA
Figure 1 | Half-maximal inhibitory concentrations (IC50) for drug assays (phenotypes). The diagonal is a histogram of the phenotypes, right diagonal is
the Spearman’s correlation between assays; left diagonal is raw data and smoothed relationship using cubic splines; DHA dihydroartemisinin, LM
lumefantrine, PPQ piperaquine, CQ chloroquine, PM pyrimethamine, MQ mefloquine, QN quinine, DEAQ desethylamodiaquine.
www.nature.com/scientificreports
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Table 1 | Association hits*
Drug Chr Position Gene Non-ref AF P-value
PPQ MAL2 846411 - 0.400 0.000175
PPQ MAL7 294258 PF07_0019 0.727 0.000467
LM MAL12 58573 - 0.591 0.000555
DHA MAL1 195090 PFA0220w 0.182 0.000273
DHA MAL13 717855 - 0.300 0.000052
DHA MAL2 514461 PFB0560w 0.227 0.000152
DHA MAL2 564143 PFB0630c 0.706 0.000323
DHA MAL6 377293 PFF0445w 0.682 0.000528
CQ MAL1 535243 PFA0665w 0.300 0.000361
CQ MAL11 466177 PF11_0127 0.714 0.000258
CQ MAL11 1984983 - 0.810 0.000334
CQ MAL12 58558 - 0.421 0.000185
CQ MAL12 58573 - 0.591 0.000555
CQ MAL12 1952993 PFL2270w 0.227 0.000532
CQ MAL12 1958385 - 0.200 0.000413
CQ MAL14 1724141 - 0.421 0.000027
CQ MAL3 638508 PFC0690c 0.182 0.000547
CQ MAL6 408695 PFF0475w 0.773 0.000304
CQ MAL7 446872 - 0.545 0.000300
CQ MAL7 447960 - 0.737 0.000172
CQ MAL7 459785 MAL7P1.27 0.524 0.000108
CQ MAL7 460214 MAL7P1.27 0.500 0.000054
CQ MAL7 461216 MAL7P1.27 0.500 0.000054
CQ MAL7 461609 MAL7P1.27 0.524 0.000108
CQ MAL7 462908 - 0.500 0.000288
CQ MAL7 952716 MAL7P1.108 0.682 0.000352
CQ MAL9 705210 - 0.350 0.000310
CQ MAL9 1280862 PFI1560c 0.682 0.000352
CQ MAL9 1280868 PFI1560c 0.682 0.000352
QN MAL12 158431 PFL0135w 0.682 0.000528
QN MAL13 103008 PF13_0075 0.318 0.000352
QN MAL13 103215 PF13_0075 0.318 0.000352
QN MAL13 1466682 PF13_0201 0.364 0.000281
QN MAL13 2636505 MAL13P1.333 0.182 0.000273
QN MAL14 908234 PF14_0215 0.667 0.000431
QN MAL14 2773249 PF14_0647 0.545 0.000300
QN MAL14 3121047 PF14_0726 0.550 0.000536
QN MAL2 70533 - 0.250 0.000258
QN MAL2 70541 - 0.250 0.000258
QN MAL2 70752 - 0.250 0.000258
QN MAL2 70779 - 0.250 0.000258
QN MAL2 70796 - 0.250 0.000258
QN MAL4 663941 PFD0700c 0.250 0.000258
QN MAL6 1287339 - 0.524 0.000380
QN MAL7 574869 - 0.368 0.000159
PM MAL1 177518 - 0.333 0.000120
PM MAL1 442138 PFA0555c 0.286 0.000442
PM MAL1 514844 PFA0650w 0.591 0.000004
PM MAL1 515098 PFA0650w 0.273 0.000188
PM MAL10 1438690 PF10_0356 0.636 0.000281
PM MAL11 1020735 PF11_0271 0.636 0.000044
PM MAL11 1263782 PF11_0334 0.773 0.000152
PM MAL14 2169608 - 0.250 0.000516
PM MAL14 3174785 - 0.611 0.000440
PM MAL2 376222 PFB0405w 0.364 0.000119
PM MAL3 651126 PFC0705c 0.591 0.000390
PM MAL3 773402 PFC0820w 0.444 0.000548
PM MAL3 921578 PFC0970w 0.727 0.000509
PM MAL4 1134664 - 0.227 0.000532
PM MAL4 1134707 - 0.227 0.000532
PM MAL6 575552 PFF0670w 0.318 0.000082
PM MAL7 1150591 PF07_0107 0.524 0.000170
PM MAL8 1312984 PF08_0002 0.455 0.000300
DEAQ MAL1 94893 - 0.333 0.000431
DEAQ MAL1 132613 PFA0150c 0.263 0.000172
DEAQ MAL1 403297 PFA0510w 0.182 0.000273
DEAQ MAL11 972835 - 0.545 0.000300
DEAQ MAL11 1228186 PF11_0327 0.273 0.000322
DEAQ MAL11 1476544 PF11_0388 0.190 0.000334
www.nature.com/scientificreports
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(PFA0220w, PFB0560w, PFA0630c, PFF1445w), (iii) 21 hits for CQ
21 (MAL7P1.108 MAL7P1.27, PF11_0127, PFA0665w, PFC0690c,
PFF0475w, PFI1560c, PFL2270w), (iv) 14 hits for QN (MAL13P1.
333, PF13_021501 PF14_0215, PF14_0647, PF14_0726, PFD0700c,
PFL0135w), (v) 1 hit for MQ (PFE1330c), (vi) 17 hits for PM
(PF07_0107, PF10_0356, PF11_0271, PF11_0334, PFA0555c, PFA06-
50w, PFB0405w, PFC0705c, PFC0820w, PFC0970w, PFF0670w) and
(vii) 19 for DEAQ (MAL8P1.157, PF07_0016, PF11_0327, PF11_
0388, PF13_0104, PF13_0254, PFA0150c, PFA0510w). These hits
were confirmed using the Spearman’s rank approach (Table S1).
Of particular interest were two SNPs associated with DHA suscept-
ibility on chromosome 13 at nucleotide positions 717855 and
1644675 (Wilcoxon, P 5 5 3 1025; Spearman’s rank, P 5 5 3
1025; Tables 1, S1) that represented the most significant hits across
all comparisons. Equally of major interest was a coding SNP (C-.G;
K873R) in PFA0220w that was found to be associated with DHA
sensitivity. A homolog of this gene was originally identified in P.
chabaudi as determinant of parasite survival in artemisinin drug
treated murine hosts (PCHAS_020720, encoding a putative deubi-
quitinase)15. Another SNP associated with DHA response implicated
PFB0630c, a gene that has homology to stress-responsive RNA poly-
merase II-binding proteins16. There was some evidence for SNP
associations in other candidate regions for the other tested drugs,
including DHFR (PM, PFD0830w, P 5 0.0173), MDR1 (MQ,
PFE1150w, P 5 0.0038), MRP2 (QN, PFL1410c, P 5 0.0052),
NHE-1 (QN, PF13_0019, P 5 0.0033), but these did not exceed the
stringent significance threshold (Table S2). Among the collected
samples we did not find evidence of the MDR1 gene (PFE1150w)
amplification, which had been found to be associated with MQ res-
istance17. Because it has recently been suggested that only a very
limited number of genes may be involved inmodifying drug suscept-
ibility18, we studied the specificity of SNP hits for a given drug by
querying the database for significant association with other drugs
(Table S2). Not a single SNP hit was associated with more than
one drug when using a moderate significance threshold for second-
ary associations (Table S2). There was a single hit for lumefantrine
(MAL7P1.30) that occurred in a region highlighted by several hits for
CQ on chromosome 7 (Table S2). The top 0.05% correlations
(corresponding to either, rho . 0.68 or p , 0.0007) were retained
from Table S1.
Signatures of recent positive selection.Drug pressure is a powerful
selective force in natural Plasmodium populations19,20. It is well
understood that positive selection acting on a beneficial trait gives
rise to characteristic regions of low genetic diversity surrounding the
causal genetic variant(s) due to the preservation of linkage
disequilibrium during meiosis (recombination in regions of 17 kb
is estimated to occur only in 1% of meioses during this life-cycle
bottleneck in the mosquito mid-gut21). Here, we sought to identify
regions of the genome under recent positive selection, as these may
represent signatures of adaptation to drug pressure (Table 2,
Figure 3). To achieve this, we calculated the integrated haplotype
score (iHS) for all 75 k SNPs across the whole genome, applying a
stringent threshold (iHS . 3.6, top 0.2%). Again in an initial vali-
dation of the analytical approach using the established chloroquine
resistance locus CRT as positive control, we found a large 45 kb
region surrounding CRT that was characterized by lower than
expected genetic diversity (PF07_0028 (2), PF07_0035 (6),
PF07_0036 (1), PF07_0037 (1),MAL7P1.30 (1), and PF07_0042 (2)).
We identified the following genes located in such ‘valleys’ of low
diversity (number of SNP hits) in the genome-wide scan: (i) PFA-
0205w (2), (ii) PFA0220w (UBP1-homologue) (1), (iii) PFC0935c (2)
(coding for a putative N-acetylglucosamine-1-phosphate transfer-
ase), (iv) PFC0940c (1), (v) PFE1210c (1), (vi) PFF1350c (13) (coding
for a putative member of the acetyl-CoA synthetase family22), (vii)
PFF1365c (2), (viii) PFF1485w (1), (ix) PF07_0004 (3), (x)
MAL7P1.207 (2), (xi) PF07_0066, (xii) a 50 kb region downstream
of PfDHPS (MAL8P1.112 (1),MAL8P1.113 (5), PF08_0100 (1), (xiii)
PFI0805w (1), (xiv) PF10_0015 (2), (xv) PF11_0074, (xvi) PF11_0420
(2), (xvii) PFL1525c (1), (xviii) PFL1835w (1), (xiix) PF14_0726 (3).
The jiHSj method may be insensitive to detect signatures of pos-
itive selection for polymorphisms that have reached fixation, we
therefore proceeded to apply the cross-population extended haplo-
type score (XP-EHH) approach to compare the Kenyan to other P.
falciparum populations (Burkina Faso, Cambodia,Mali, Thailand) to
identify evidence for positive selection of alleles that have reached or
are near fixation in individual populations23. The analysis confirms
selection acting on PfCRT across all comparisons, but also at the
PfDHPS locus across African populations (Fig. S2).
In our analysis of genomic regions with low diversity, we also
found the current vaccine candidates MSP1 (2), AMA1 (4) (prev-
iously described by Mu et al.24), and TRAP (6). This was a surprising
finding because these genes are thought to be targets of protective
immunity and are known to contain extensive SNP and/or repeat
polymorphisms. To obtain reassurance that our finding did not
result from spurious genomic data, we implemented the Tajima’s
Dmetric25, an approach for distinguishing between a DNA sequence
evolving randomly (‘‘neutrally’’, values close to zero) and one evol-
ving under a non-random process, including directional selection
(low negative values) or balancing selection (high positive values).
Table 1 | Continued
Drug Chr Position Gene Non-ref AF P-value
DEAQ MAL13 786385 PF13_0104 0.714 0.000442
DEAQ MAL13 1942726 PF13_0254 0.227 0.000152
DEAQ MAL2 849778 - 0.545 0.000207
DEAQ MAL2 849818 - 0.545 0.000207
DEAQ MAL2 849823 - 0.545 0.000207
DEAQ MAL2 849837 - 0.545 0.000207
DEAQ MAL2 849896 - 0.545 0.000207
DEAQ MAL3 448562 - 0.182 0.000273
DEAQ MAL4 1136713 - 0.211 0.000516
DEAQ MAL7 254907 PF07_0016 0.227 0.000152
DEAQ MAL7 254910 PF07_0016 0.227 0.000152
DEAQ MAL8 116107 MAL8P1.157 0.318 0.000352
DEAQ MAL8 311608 - 0.211 0.000516
DEAQ MAL8 452012 PF08_0105 0.286 0.000442
MQ MAL5 1119259 PFE1330c 0.818 0.000547
*Wilcoxon non-parametric tests with P , 0.006 are presented; DHA dihydroartemisinin, LM lumefantrine, PPQ piperaquine, CQ chloroquine, PM pyrimethamine, MQ mefloquine, QN quinine, DEAQ
desethylamodiaquine.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3318 | DOI: 10.1038/srep03318 4
Indeed when calculating the Tajima’s D on a gene-by-gene basis we
found 18 loci, including AMA1, MSP3, MSP3.8, MSP6 vaccine can-
didates (Table S3). These results could indicate the co-existence of
reverse selective forces on different domains and/or upstream and
downstream regulatory elements of the same gene. For instance,
purifying selection could act on functional domains such as trans-
membrane stretches or functional motives while at the same time,
diversifying selection acts on immunologically exposed extracellular
loops26. Alternatively, the co-existence of hyper-variable ‘islands’
within regions of lower than expected diversity may point to a prev-
iously unrecognized feature of chromosome biology that is providing
a pathway for diversification at amino acid residues or entire
domains exposed to adaptive immune responses.
Association and selection by gene. Recent positive selection of
survival-promoting genotypes, such as drug resistance-conferring
mutations, should be detectable both by genotype-phenotype
association and by ‘phenotype-free’ analysis of genomic structures
(see above section on signatures of recent positive selection) as long
as (i) selective pressure has had sufficient time to shape evolution or
on the opposite end of the evolutionary time scale, (i) the causal
genetic variant has not yet reached fixation in the population (i.e.,
close to 100% prevalence). We used a simple composite score
(termed ‘total evidence score’, TES) calculated as the sum of the
negative decadic logarithm (2log10) of the P-value for association
and the iHS score for unusually large haplotypes for each of the
75,471 high-quality bi-allelic SNPs (Figure 4 and Table S4).
Among the top twenty highest ranked SNPs, we found CRT
(MAL7P1.27), Cg1 (immediately downstream of CRT), and UBP1.
Of the 44 genes (1.7% of 2591 passing QC) identified by selection or
Table 2 | Signatures of recent positive selection*
Chromosome Position frequency Allele Gene iHS
MAL1 180291 0.130 A PFA0205w 3.941
MAL1 180421 0.717 A PFA0205w 5.118
MAL1 192889 0.217 G PFA0220w 3.652
MAL2 839683 0.152 A PFB0935w 3.669
MAL3 137202 0.870 A PFC0120w 4.850
MAL3 884959 0.109 A PFC0935c 4.843
MAL3 884962 0.109 A PFC0935c 4.844
MAL4 545613 0.109 G PFD0595w 3.611
MAL4 611365 0.717 G - 3.810
MAL4 805223 0.065 G PFD0872w 3.763
MAL4 994422 0.065 C PFD1030c 3.982
MAL4 1148234 0.630 A PFD1215w 3.958
MAL4 1148261 0.522 A PFD1215w 3.692
MAL5 929750 0.457 G PFE1120w 3.621
MAL5 1011110 0.391 C PFE1210c 3.799
MAL6 1030822 0.304 G PFF1225c 3.677
MAL6 1114493 0.500 A - 4.840
MAL6 1114518 0.543 A - 4.154
MAL6 1114565 0.565 G PFF1350c 3.973
MAL6 1114588 0.543 A PFF1350c 4.201
MAL6 1114626 0.543 A PFF1350c 4.201
MAL6 1114909 0.543 C PFF1350c 4.201
MAL6 1114929 0.543 A PFF1350c 4.201
MAL6 1114952 0.543 C PFF1350c 4.201
MAL6 1115373 0.565 G PFF1350c 4.846
MAL6 1115454 0.587 A PFF1350c 4.802
MAL6 1116047 0.609 T PFF1350c 4.853
MAL6 1116102 0.587 T PFF1350c 4.786
MAL6 1116171 0.609 A PFF1350c 4.730
MAL6 1116315 0.587 T PFF1350c 4.821
MAL6 1117520 0.609 A PFF1350c 3.786
MAL6 1128749 0.543 G PFF1365c 4.064
MAL6 1132351 0.500 G PFF1365c 3.959
MAL6 1268976 0.348 C PFF1470c 4.036
MAL6 1271588 0.217 T - 4.432
MAL6 1282898 0.196 T PFF1485w 4.929
MAL6 1283740 0.087 T - 4.064
MAL7 430849 0.391 T PF07_0028 3.763
MAL7 431906 0.326 C PF07_0028 3.860
MAL7 465618 0.870 C PF07_0035 3.716
MAL7 465787 0.478 C PF07_0035 6.267
MAL7 465791 0.543 A PF07_0035 4.825
MAL7 465810 0.587 T PF07_0035 4.109
MAL7 466389 0.261 T PF07_0035 3.963
MAL7 466988 0.457 T PF07_0035 4.196
MAL7 467844 0.370 A PF07_0036 4.568
MAL7 476798 0.370 G PF07_0037 3.732
MAL7 503466 0.717 G MAL7P1.30 3.850
MAL7 520886 0.109 A PF07_0042 3.626
MAL7 524323 0.065 T PF07_0042 4.668
MAL7 665933 0.152 C - 3.713
MAL7 761532 0.087 G PF07_0066 4.206
MAL7 1440395 0.370 C - 4.991
MAL8 469790 0.304 T PF08_0102 3.840
MAL8 479954 0.174 C - 3.632
MAL8 491667 0.239 A MAL8P1.113 5.274
MAL8 491757 0.217 C MAL8P1.113 5.665
MAL8 491831 0.217 G MAL8P1.113 5.853
MAL8 491883 0.217 C MAL8P1.113 5.856
MAL8 492065 0.587 T MAL8P1.113 4.366
MAL8 502511 0.304 A PF08_0100 4.319
MAL8 506087 0.283 T MAL8P1.112 4.061
MAL9 599641 0.087 G PFI0685w 3.867
MAL9 689167 0.891 A PFI0805w 4.711
MAL9 1202400 0.065 T PFI1475w 3.920
MAL9 1202416 0.065 A PFI1475w 3.920
MAL9 1202437 0.065 T PFI1475w 3.920
MAL9 1202504 0.065 C PFI1475w 3.921
MAL10 61593 0.304 A - 4.516
Table 2 | Continued
Chromosome Position frequency Allele Gene iHS
MAL10 68880 0.065 C PF10_0015 3.600
MAL10 68888 0.065 A PF10_0015 3.660
MAL10 879301 0.065 G PF10_0211 3.873
MAL10 1524131 0.522 A PF10_0374 3.784
MAL10 1524172 0.370 T PF10_0374 3.862
MAL10 1543093 0.478 A PF10_0374 4.313
MAL11 265298 0.065 T PF11_0074 4.526
MAL11 681352 0.717 G PF11_0185 4.136
MAL11 681360 0.739 G PF11_0185 4.185
MAL11 1294582 0.261 A PF11_0344 6.442
MAL11 1294701 0.348 C PF11_0344 4.887
MAL11 1294706 0.217 C PF11_0344 6.074
MAL11 1294751 0.370 A PF11_0344 4.403
MAL11 1637771 0.087 T PF11_0420 3.604
MAL12 57132 0.109 G - 5.100
MAL12 57138 0.152 T - 4.183
MAL12 95229 0.152 A PFL0070c 3.764
MAL12 1579059 0.196 G PFL1835w 4.093
MAL13 1465418 0.152 C PF13_0201 4.118
MAL13 1465808 0.130 C PF13_0201 3.624
MAL13 1465878 0.478 C PF13_0201 4.519
MAL13 1465929 0.543 C PF13_0201 4.213
MAL13 1465950 0.478 G PF13_0201 3.931
MAL13 1466282 0.804 C PF13_0201 3.900
MAL13 1466322 0.370 C PF13_0201 4.446
MAL13 1466429 0.913 T PF13_0201 4.973
MAL13 1466471 0.283 A PF13_0201 3.921
MAL14 542167 0.087 A PF14_0135 4.274
MAL14 1986848 0.891 T PF14_0463 3.759
MAL14 1986850 0.913 T PF14_0463 3.984
MAL14 3121318 0.348 T PF14_0726 3.625
MAL14 3121371 0.261 C - 4.836
MAL14 3121449 0.174 G PF14_0726 5.866
*using the integrated haplotype score (iHS, absolute values .3.6 are presented).
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association (Table S4), only UBP1, CRT and surrounding loci
(PF07_0035), and PF14_0726 gene regions were identified by both
approaches, providing stronger evidence for their role in modulating
drug sensitivity. The biological relevance of a modest correlation
between association P-values and selection tests (Spearman’s
correlation 0.41) at a gene level in entire P. falciparum genomes is
not clear and it may be an artifact stemming from limits to attain
significance with low frequency variants in both tests (Fig. 4).
The collected samples were all resistant to pyrimethamine, and
there is some evidence of a selective sweeps within 50 kb of the
DHFR gene and in the 3’ region of DHPS (which encodes the
target of sulfadoxine, involved in the combination therapy with
pyrimethamine). The iHS metric is powered to detect sweeps only
at intermediate frequency and prior to fixation. This could explain
the failure to detect a stronger signal in our samples, all of which
were resistant to pyrimethamine in vitro and carried the resist-
ance-conferring gatekeeper mutation at codon position 108
(S108N).
Discussion
The identification of loci associated with malarial drug resistance
has the potential to support disease surveillance systems and pro-
vide public health bodies with the information needed to deliver
effective interventions. Here we studied associations between (i)
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Figure 2 | Manhattan plots of whole genome association tests. X-axis is Chromosomes 1 to 14 in alternating colors; Y-axis is the2log10 p-value from a
Wilcoxon test; points in blue indicate P-values less than 0.0007 (above horizontal dashed line); DHA dihydroartemisinin (Fig. 2A), LM lumefantrine
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whole-genome sequence variation at single-nucleotide resolution
obtained through next-generation sequencing technology and (ii)
robust drug susceptibility phenotypes obtained through repeat in
vitro experiments with the aim to discover novel genes or genomic
regions that modify drug susceptibility in 27 isolates of P. falci-
parum collected from Kenyan patients with malaria.
The power of our approach could be demonstrated in an initial
proof-of-principle screen for chloroquine resistance-associated
genes. The most significant association was found for the CRT gene
that encodes the well-characterized chloroquine resistance trans-
porter27,28. When extending the analysis to seven important antima-
larial drugs, including dihydroartemisinin as both active metabolite
and component of the current front-line artemisinin-based com-
bination therapies, we identified several additional loci that were
strongly associated with drug response phenotypes (Table 1 and
Fig. 2A–H). Because of the urgency of the artemisinin resistance
problem1–3, we focused on specific hits associatedwith the dihydroar-
temisinin response phenotype. We could confirm the previously
reported association with PFA0220w, a homologue of UBP1 prev-
iously identified in a rodent malaria model and coding for a putative
de-ubiquitinating protein15,29, and we identified three novel candid-
ate genes (PFB0560w, PFB0630c, PFF0445w). Of note, our screen also
identified a SNP (MAL13-1644675) located in a 35-kb segment on
chromosome 13 that was recently linked to delayed in vivo clearance
in P. falciparum infections from Western Thailand30. PFB0630c
shares homology with the human RPAP2 protein and the yeast
Rtr1 protein16 with putative regulatory roles in RNA polymerase
II function. This may be of interest in the light of the reported
differential expression pattern observed in isolates obtained from
P. falciparum infections with delayed in vivo responses in Cambo-
dia31. PFB0560w and PFF0445w are conserved Plasmodium protein
coding genes with no assigned putative functions. PFF0445w had
previously been reported to be up-regulated in response to artemi-
sinin pressure in vitro in a comparative proteomics study32. The
functional relevance of the chromosome 13 hit (MAL13-1644675;
correlation rho 5 0.7; P 5 0.001), centered between the predicted
open reading frames MAL13P1.211 (21 kb, coding for a hypothet-
ical protein with no predicted function) and PF13_0226 (1.7 kp,
predicted to code for an inner membrane complex (IMC) protein)
is not known.
We also screened for evidence of recent positive selection in the
genomes of our samples. Of particular interest was a strong signal
surrounding PFA0220w (UBP1-homologue) (Fig. S1). However, we
did not detect a similar selection signal for MAL13-1644675 in a 35-
kb segment on chromosome 13 that was recently linked to delayed in
vivo clearance in P. falciparum infections from Western Thailand30.
The fact that our screen identified an isolated association at this locus
without a signal for recent positive selection may be explained by the
evolutionary time point of sampling: artemisinin-based combination
therapy was introduced as first-line treatment only 2–3 years before
sampling started33. This hypothesis is supported by evidence for the
chloroquine resistance gene CRT where both association and
signature of selection are present in our data, most likely as a result
of longstanding drug pressure19,34. The absence of significantly
delayed P. falciparum infections in Kilifi after artemisinin treatment
despite themoderate allele frequency ofMAL13-1644675 in the local
Figure 3 | Evidence of recent positive selection.We used the integrated Haplotype Score (iHS), where points above the horizontal dashed line indicated
scores in excess of 3.6; x-axis is Chromosomes 1 to 14 in alternating colors; vertical lines correspond to chromosomal locations ofDHFR,MDR1, andCRT,
DHPS, respectively (left to right). Larger sized points indicate significant results in unique, non-telomeric and non-highly variable gene regions.
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parasite population suggests that this, or yet unknown causal, genetic
variants in this region on chromosome 13 are required but not suf-
ficient for full blown in vivo artemisinin tolerance. Of note, a gen-
ome-wide analysis for associations of genotypes with the rate of
parasite clearance after treatment with artemisinin-based combina-
tions in patients who donated the P. falciparum isolates for this study
(presence or absence of microscopically detectable blood stage para-
sites on day 29) did not reveal significant signals (Fig. S2).
In this study we used a panel of 8 commonly used antimalarial
drugs to determine robust chemosensitivity phenotypes. This focus
on in vitro data was motivated by a lack of correlation between the
reported delayed in vivo response to artemisinins and the in vitro
phenotype in most1,9, if not all2, studies. Whilst an in vivo phenotype
would have been preferred, these phenotypes are difficult tomeasure,
and the outcome can be confounded by host genetic, immunity and
intra-assay variation. In contrast, the IC50 values measured in 27 P.
falciparum isolates obtained from pediatric patients in Kilifi District
on the Kenyan Coast exhibited substantial phenotypic variation
(mean.10-fold; Fig. 1) and a high degree of inter-assay reproducib-
ility. The observed pattern of correlations between drug responses
was also consistent with previously published data, reinforcing the
confidence in the accuracy of the phenotypes.
In general, complex genetic traits may involve many genes, each
of small effect magnitude. However, drug resistance in P. falci-
parum has been reported as strong single locus effects, with bene-
ficial alleles rapidly going to fixation by selective sweeps leaving
characteristic low-diversity ‘scars’ in the genomes of resistant
parasites. In practice, that translates into smaller sample size
requirements for detecting selection events, compared to asso-
ciation studies for complex traits35. To account for the potential
number of false positives, we applied stringent quality control on
the polymorphisms included, a conservative non-parametric test-
ing and an adjusted statistical significance threshold. Our approa-
ch relied on natural variation in the parasite, leading to a set of strong
candidates, including hitherto unexpected pathways. For instance, the
associations of TRAP and of PF14_0647 (coding for a putative Rab
GTPase activator) with sensitivity to quinine (a known ion channel
blocker36,) (Table 1) may point to a role of membrane-associated
trafficking in the mechanism of action of quinine.
Our approach is conceptually similar to a study by Mu et al.24
but with .20 times higher resolution of genetic variation, and with
a focus on a single local parasite population obtained from patients in
a well-described cohort9,37 to reduce potential confounding by
population structure. In contrast to Mu et al.24 we found one gene
(PFA0655w) to be associated with chloroquine, and not mefloquine
or dihydroartemisinin, sensitivity and we failed to find evidence for
MDR1. Another study by vanTyne et al.38 also reported on a genome-
wide association study using an array-based genotyping strategy.
There was partial overlap in the drugs used and specifically, we could
not confirm a gene (PF14_0654) associated with artemisinin sens-
itivity, possibly related to a lack of power in our small sample size. A
parallel study by Park et al.39 could also confirm the efficiency of
massively parallel shot-gun sequencing by employing a related
strategy designed to increase the resolution of an initial positive
Figure 4 | Scatter plot of evidence scores from genotype-phenotype association and genomic structure analyses. Values of iHS or 2log10 P-value
from association testing are presented, with the gene names that exceed thresholds (blue: iHS . 3.6 or p , 0.0007; red: iHS . 3 or p , 0.001). The
Spearman’s correlation is 0.417 (P , 0.00001).
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selection-based screen by using association test results39. In contrast
to Park et al., however, we did not assume selection through drug
pressure to be driving allele frequencies conferring tolerance to the
artemisinins relatively shortly after the introduction of artemisinin-
based combination chemotherapies. Consequently, we used genomic
signatures of positive selection not as a primary screen but as an
additional parameter for identifying genes and/or genomic regions
associated with artemisinin response rates through non-parametric
genotype-phenotype association tests.
In summary, our study in a limited number of P. falciparum iso-
lates has shown that a natural genetics approach powered by whole
genome sequencing using new short read technologies can identify
novel chemosensitivity-determining genes, applied particularly
within a robust genome-wide association and selection setting.
These results show promise for geographically focused and timely
sequence-based studies as a powerful and efficient tool in future
disease surveillance programs. We found substantial overlap with
previously reported artemisinin resistance-associated candidate
genes and regions (prominently, PFA0220w, a UBP1-homologue
and a 35-kb segment on chromosome 13). Because the studied iso-
lates did not originate from artemisinin resistant infections, we hypo-
thesize that the observed associations indicate standing variation that
could serve as substrate for selection under continued drug pressure.
It also provides a unique reference for the interpretation of results
from resistant infections.
Methods
In vitro phenotypes.The study was approved by the National KEMRI Ethical Review
Committee, Kenya; the Oxford Tropical Research Ethics Committee, UK; and the
Ethics Committee, Heidelberg University School of Medicine, Germany. Parasite
isolates were obtained in 2007 to 2008 from patients presenting with uncomplicated
episodes of P. falciparummalaria before initiation of treatment with an artemisinin-
based combination therapy (n 5 13) and when patients experienced recurrence of
infection during follow-up (n 5 14)9. Cryo-preserved isolates were consecutively
thawed and adapted to cell culture conditions. Parasites were cultured in complete
medium (RPMI supplemented with L-glutamine, 2% heat-inactivated AB serum,
0.1 mM hypoxanthine, gentamicin, and albumax II) in the presence of O1 or A1
blood at 5% packed cell volume and a gas mixture of 5% CO2, 5% O2 and 90% N2.
Growth inhibition of parasite cultures at 0.5% packed cell volume and 0.1%
parasitemia was determined on 96-well plates by exposure to serial dilutions of
dihydroartemisinin (DHA, Sigma), lumefantrine (LM, Novartis), piperaquine (PPQ,
SigmaTau), chloroquine (CQ, Sigma), pyrimethamine (PM, Sigma),mefloquine (MQ,
Sigma), N-desethylamodiaquine (DEAQ, Sigma) and quinine (QN, Sigma). After
incubation at 37uC for 72 hours, 20 nM SYBR green in lysis buffer (20 mMTris at pH
7.5, 5 mM EDTA, 0.008% (wt/vol) saponin, and 0.08% (vol/vol) Triton X-100)
(doi:10.1128/AAC.01607-06) was added and fluorescence intensity measured at
20 nm (model, manufacturer). Growth inhibition experiments were repeated at least
twice (mean, 3.1). Half-maximal inhibitory concentrations (IC50) were estimated by
non-linear regression.
Sequencing and genetic variant analysis. All samples (n 5 27) underwent whole
genome sequencing, with 54 or 76-base paired end fragment sizes, using Illumina
technology (see40 for a description), and processed as previously described41 to
identify variation including SNPs and small insertions and deletions. In brief, we
mapped all isolates to the 3D7 (version 3.0) reference genome using smalt (5), and
called variants using samtools (6). Sequence polymorphisms were identified
empirically using sequence coverage data as previously described (4). The internal
replicability and correlation between in vitro phenotypes was assessed using
Spearman’s correlation. Geographical outliers were identified using a principal
component clustering approach applied to multi-continental SNP data (40, Short
read archive (SRA) Study ERP000190). The integrated haplotype score (iHS, (12))
method was applied to SNPs data to identify long-range directional selection. The
selection metric Tajima’s D25 was used for distinguishing between a DNA
sequence evolving randomly (‘‘neutrally’’, values close to 0) and one evolving
under a non-random process, including directional selection (low negative values)
or balancing selection (high positive values). Because of the non-symmetry of
phenotypes, the primary assessment of association between phenotypes and
genetic variants (alleles) used Wilcoxon rank tests. A secondary analysis applied
Spearman’s correlation. A statistical significance cut-off (P 5 0.0007, 2log10 P 5
3.15) was inferred by simulation (phenotype-based permutation) to represent a
multiple test adjustment of a nominal 5% error rate. For the final hits, we
considered only genomic variants in regions that were unique (calculated by
sliding 50 base pairs of contiguous sequence across the reference genome), non-
subtelomeric, and not in highly variable gene families (rifins, surfins, stevors, and
vars). Regions for follow-up were compared to publically available sequence
data40,42. All raw sequencing data for this work is contained in SRA study
ERP000190.
1. Dondorp, A. M. et al. Artemisinin resistance in Plasmodium falciparum malaria.
N Engl J Med 361, 455–67 (2009).
2. Noedl, H. et al. Evidence of artemisinin-resistant malaria in western Cambodia.
N Engl J Med 359, 2619–20 (2008).
3. Phyo, A. P. et al. Emergence of artemisinin-resistant malaria on the western
border of Thailand: a longitudinal study. Lancet (2012).
4. Eastman, R. T. & Fidock, D. A. Artemisinin-based combination therapies: a vital
tool in efforts to eliminate malaria. Nat Rev Microbiol 7, 864–74 (2009).
5. Nayyar, G., Breman, J., Newton, P. & Herrington, J. Poor-quality antimalarial
drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12, 488–496
(2012).
6. Rathod, P. K., McErlean, T. & Lee, P. C. Variations in frequencies of drug
resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 94, 9389–93
(1997).
7. Bjorkman, J., Nagaev, I., Berg, O. G., Hughes, D. & Andersson, D. I. Effects of
environment on compensatory mutations to ameliorate costs of antibiotic
resistance. Science 287, 1479–82 (2000).
8. Mackinnon, M. J. & Marsh, K. The selection landscape of malaria parasites.
Science 328, 866–71 (2010).
9. Borrmann, S. et al. Declining responsiveness of Plasmodium falciparum
infections to artemisinin-based combination treatments on the Kenyan coast.
PLoS ONE 6, e26005 (2011).
10. Sidhu, A. B. et al. Decreasing pfmdr1 copy number in plasmodium falciparum
malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine,
quinine, and artemisinin. J Infect Dis 194, 528–35 (2006).
11. Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. & Meshnick, S. R.
Epidemiology of drug-resistant malaria. Lancet Infect Dis 2, 209–18 (2002).
12. Witkowski, B. et al. Novel phenotypic assays for the detection of artemisinin-
resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo
drug-response studies. Lancet Infect Dis (2013).
13. Gardner,M. J. et al. Genome sequence of the humanmalaria parasite Plasmodium
falciparum. Nature 419, 498–511 (2002).
14. van Schalkwyk, D. A. et al. Culture-adapted Plasmodium falciparum isolates from
UK travellers: in vitro drug sensitivity, clonality and drug resistance markers.
Malar J 12, 320 (2013).
15. Hunt, P. et al. Experimental evolution, genetic analysis and genome re-sequencing
reveal the mutation conferring artemisinin resistance in an isogenic lineage of
malaria parasites. BMC Genomics 11, 499 (2010).
16. Gibney, P. A., Fries, T., Bailer, S. M. & Morano, K. A. Rtr1 is the Saccharomyces
cerevisiae homolog of a novel family of RNA polymerase II-binding proteins.
Eukaryot Cell 7, 938–48 (2008).
17. Price, R. N. et al. Mefloquine resistance in Plasmodium falciparum and increased
pfmdr1 gene copy number. Lancet 364, 438–47 (2004).
18. Yuan, J. et al. Chemical genomic profiling for antimalarial therapies, response
signatures, and molecular targets. Science 333, 724–9 (2011).
19. Wootton, J. C. et al. Genetic diversity and chloroquine selective sweeps in
Plasmodium falciparum. Nature 418, 320–3 (2002).
20. Roper, C. et al. Intercontinental spread of pyrimethamine-resistant malaria.
Science 305, 1124 (2004).
21. Su, X. et al. A genetic map and recombination parameters of the human malaria
parasite Plasmodium falciparum. Science 286, 1351–3 (1999).
22. Bethke, L. L. et al. Duplication, gene conversion, and genetic diversity in the
species-specific acyl-CoA synthetase gene family of Plasmodium falciparum.Mol
Biochem Parasitol 150, 10–24 (2006).
23. Sabeti, P. C. et al. Genome-wide detection and characterization of positive
selection in human populations. Nature 449, 913–8 (2007).
24. Mu, J. et al. Plasmodium falciparum genome-wide scans for positive selection,
recombination hot spots and resistance to antimalarial drugs. Nat Genet 42,
268–71 (2010).
25. Tajima, F. Statistical method for testing the neutral mutation hypothesis by DNA
polymorphism. Genetics 123, 585–95 (1989).
26. Amambua-Ngwa, A. et al. SNP genotyping identifies new signatures of selection
in a deep sample of West African Plasmodium falciparum malaria parasites.Mol
Biol Evol 29, 3249–53 (2012).
27. Fidock, D. A. et al. Mutations in the P. falciparum digestive vacuole
transmembrane protein PfCRT and evidence for their role in chloroquine
resistance. Mol Cell 6, 861–71 (2000).
28. Sidhu, A. B., Verdier-Pinard, D. & Fidock, D. A. Chloroquine resistance in
Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science
298, 210–3 (2002).
29. Hunt, P. et al. Gene encoding a deubiquitinating enzyme ismutated in artesunate-
and chloroquine-resistant rodent malaria parasites. Mol Microbiol 65, 27–40
(2007).
30. Cheeseman, I. H. et al. A major genome region underlying artemisinin resistance
in malaria. Science 336, 79–82 (2012).
31. Mok, S. et al. Artemisinin resistance in Plasmodium falciparum is associated with
an altered temporal pattern of transcription. BMC Genomics 12, 391 (2011).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3318 | DOI: 10.1038/srep03318 9
32. Prieto, J. H., Koncarevic, S., Park, S. K., Yates, J. 3rd & Becker, K. Large-scale
differential proteome analysis in Plasmodium falciparum under drug treatment.
PLoS ONE 3, e4098 (2008).
33. Dondorp, A. M. et al. Artemisinin resistance: current status and scenarios for
containment. Nat Rev Microbiol 8, 272–80.
34. Mwai, L. et al. Chloroquine resistance before and after its withdrawal in Kenya.
Malar J 8, 106 (2009).
35. Anderson, T., Nkhoma, S., Ecker, A. & Fidock, D. How can we identify parasite
genes that underlie antimalarial drug resistance? Pharmacogenomics 12, 59–85
(2011).
36. DeCoursey, T. E., Chandy, K. G., Gupta, S. & Cahalan, M. D. Voltage-gated K1
channels in human T lymphocytes: a role in mitogenesis? Nature 307, 465–8
(1984).
37. Olotu, A. et al. Defining clinical malaria: the specificity and incidence of endpoints
from active and passive surveillance of children in rural Kenya. PLoS ONE 5,
e15569 (2010).
38. Van Tyne, D. et al. Identification and functional validation of the novel
antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genet
7, e1001383 (2011).
39. Park, D. J. et al. Sequence-based association and selection scans identify drug
resistance loci in the Plasmodium falciparummalaria parasite. Proc Natl Acad Sci
U S A 109, 13052–7 (2012).
40. Manske, M. et al. Analysis of Plasmodium falciparum diversity in natural
infections by deep sequencing. Nature 487, 375–9 (2012).
41. Robinson, T. et al. Drug-resistant genotypes and multi-clonality in Plasmodium
falciparum analysed by direct genome sequencing from peripheral blood of
malaria patients. PLoS ONE 6, e23204 (2011).
42. MalariaGen. Sequence Read Archive. (Accessed on 10 Oct 2013). http://www.
malariagen.net/data/sequence-read-archive.
Acknowledgments
We thank Ines Petersen for helpful comments and Bronwyn MacInnis for assistance. This
work is published with the permission of the Director of KEMRI. This work was supported
by a German Research Foundation (DFG) grant to S.B. The funding source had no role in
the design of the study; in the collection, analysis, and interpretation of data; in the writing
of the report; and in the decision to submit the paper for publication.
Author contributions
S.B. and T.C. wrote the manuscript. S.B., A.N., D.K. and T.C. designed the study. S.B., J.S.
and T.C. analysed the data. L.M., A.A., A.R., J.O., S.M., M.M.K., S.C. and S. Auburn
generated data. P.S. and B.L. oversaw sample collection. S. Assefa, M.M. and G.M. provided
data analysis tools and assisted data analysis. N.P. and K.M. coordinated the clinical study.
All authors have reviewed the manuscript.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Borrmann, S. et al. Genome-wide screen identifies new candidate
genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci.
Rep. 3, 3318; DOI:10.1038/srep03318 (2013).
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-sa/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 3318 | DOI: 10.1038/srep03318 10
